A Dose Ascending, Open Phase I Clinical Study to Evaluate the Safety, Tolerability and Pharmacokinetics Characteristics of VG161 in Subjects With Advanced Malignant Solid Tumors
Latest Information Update: 05 Apr 2023
At a glance
- Drugs VG 161 (Primary)
- Indications Carcinoma; Solid tumours
- Focus Adverse reactions
- Sponsors Virogin Biotech
- 26 Apr 2021 Status changed from not yet recruiting to recruiting.
- 19 Feb 2021 New trial record